Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
Volume 9, Issue 9, Pages 3487-3489Publisher
ELSEVIER
DOI: 10.1016/j.jaip.2021.06.032
Keywords
-
Categories
Ask authors/readers for more resources
Patients with mast cell disorders can safely receive the BNT162b2 mRNA COVID-19 vaccine without the need for specific measures.
The BNT162b2 mRNA COVID-19 vaccine is safe and well-tolerated in patients with mast cell disorders. These patients can be immunized with this vaccine with no need for specific measures.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available